India, July 11 -- Valneva SE (VALN) announced that the European Medicines Agency - EMA has lifted its temporary restriction on administering the chikungunya vaccine IXCHIQ to individuals aged 65 and above.
This decision follows a thorough review by the EMA's Pharmacovigilance Risk Assessment Committee or PRAC, which was initiated in May due to reports of serious side effects mainly in elderly patients with multiple underlying conditions.
The EMA reaffirmed that IXCHIQ is contraindicated for immunocompromised individuals and emphasized that vaccination for all age groups should occur only when there is a significant risk of chikungunya infection, weighing potential benefits against risks. The committee acknowledged that while most adverse ...